
TAST 2011 — Thrombolysis and Acute Stroke Treatment in 2011
Thursday, December 1, 2011 - Saturday, December 3, 2011
Presented By
Presented by the New York Academy of Sciences
Designed to serve a multidisciplinary audience of physicians, clinicians, and scientists interested in cerebrovascular disease, this 2.5-day conference will explore the state-of-the-art and future directions of research and clinical practice leading to enhanced medical care in the acute treatment of ischemic stroke.
The majority of strokes are due to thrombotic or thromboembolic blockage of an artery supplying the brain. Prompt treatment with thrombolytic agents can restore blood flow, limiting brain damage and improving recovery prognosis after ischemic stroke. Use of thrombolytic agents, including recombinant tissue-type plasminogen activator (rt-PA), over the past thirty years has enhanced patient outcomes, but has also highlighted many other aspects of the medical setting that impact treatment success. This symposium will explore these facets of acute intervention and a number of unaddressed issues related to the medical setting of stroke that provide opportunities for improving treatment. Following on ten previous international symposia on the theme of thrombolytic treatment in acute ischemic stroke (i.e. TTAST, TAST), the New York Academy of Sciences is proud to undertake the 11th meeting in this series (TAST 2011) to focus on these issues.
The program will feature keynote and plenary lectures, short oral and poster presentations selected from abstract submissions, a mini-symposium, and a hands-on workshop on Advanced Multi-modal Neuroimaging and Ultrasound Techniques. There will be multiple opportunities for audience and panel discussion. Speakers will be asked to respond to sets of questions during their presentations to foster the generation of data-driven, multidisciplinary ideas, to explore ischemic stroke as a systemic disease related to other disease entities (hypertension, diabetes, and disorders of aging), and to better address the evolution of ischemic brain injury.
Highlighted topics include: (i) the neurovascular unit and its injury; (ii) the safety and efficacy of thrombolytic agents currently used or being developed for acute stroke treatment; (iii) new views of the penumbra; (iv) time window considerations and optimized delivery conditions; (v) stabilization of brain tissue for patient recovery; (vi) enhancing the safety of plasminogen activators; (vii) factors that influence risk and benefit; and (viii) alternative approaches in stroke treatment.
Live Webinar for Session II
Session II: Clinical Management of Medical Issues in the Acute Setting will be broadcast via live webinar on December 2nd, 2:00–5:20 pm. You can register for this webinar by clicking the Register for Webinar link, above.
Registration Pricing
By: 11/30/2011 | Onsite: 12/01/2011 | |
Member | $350 | $450 |
Student / Postdoc / Fellow Member | $175 | $225 |
Student / Postdoc / Fellow Nonmember | $175 | $225 |
Nonmember Corporate | $575 | $675 |
Nonmember Not for Profit | $450 | $550 |
Registration for the conference includes the option to RSVP for the satellite workshop preceding the scientific sessions on December 1, 2011 from 1–5 pm, Advanced Multi-modal Neuroimaging and Ultrasound Approaches to Hyperacute Stroke Diagnosis, Treatment, and Monitoring, at no extra cost. Participants interested in this workshop only may register to attend only this satellite session at www.nyas.org/tast2011workshop. |
Scientific Co-Organizers
Gregory J. del Zoppo, MD
University of Washington School of Medicine
Andrei V. Alexandrov, MD
University of Alabama at Birmingham
Scientific Advisory Committee
Etsuro Mori, MD, PhD
Tohoku University
Markku Kaste, MD, PhD
Helsinki University
John R. Marler, MD
Rockville, MD
International Advisory Board
Gudrun Boysen, MD
University of Copenhagen
Thomas G. Brott, MD
The Mayo Clinic
Alastair Buchan
University of Oxford
László Csiba, MD, PhD
University of Debrecen
Steven M. Davis, MD
University of Melbourne
Andrew Demchuk, MD
University of Calgary
Geoffrey Donnan, MD
Florey Neuroscience Institutes
Werner Hacke, MD, PhD
University of Heidelberg
Karsten Overgaard, MD
University Hospital of Copenhagen, Gentofte Hospital
Shirley Otis, MD
Scripps Clinic–La Jolla
Paul Trouillas, MD
Hôpital Neurologique
Lawrence Wong, MD, FRCP
Chinese University of Hong Kong
Take Yamaguchi, MD
National Cardiovascular Center
This meeting is part of our Translational Medicine Initiative, sponsored by the Josiah Macy Jr. Foundation and The Mushett Family Foundation.
For a full list of sponsors, please view the Sponsors tab.
Agenda
* Presentation times are subject to change.
Day 1: Thursday, December 1, 2011 | |
SATELLITE WORKSHOP | |
Advanced Multi-modal Neuroimaging and Ultrasound Approaches to Hyperacute Stroke Diagnosis, Treatment, and Monitoring (Optional) * * Registration for this workshop is included in the conference registration; if you wish to register for this workshop only, visit www.nyas.org/tast2011workshop | |
12:30 PM | Registration |
Tutorial Session | |
1:00 PM | Advanced Multimodal CT/MRI Approaches to Hyperacute Stroke Diagnosis, Treatment and Monitoring |
1:45 PM | Multimodal Neuroimaging: Ultrasound and Catheter Angiography (including a 10-minute demo) |
Hands-on Demonstrations | |
2:30 PM | Ultrasound examination and monitoring demonstrations provided by: |
Case / Interactive Problem-solving Session | |
3:30 PM | 5 cases studies (Using Audience Response System) |
5:00 PM | Workshop Concludes |
CONFERENCE | |
4:30 PM | Registration Conference and Poster Set-up |
5:30 PM | Opening Remarks |
6:00 PM | Keynote Address 1 |
6:50 PM | Reception and Poster Viewing |
8:20 PM | Day 1 Concludes |
Day 2: Friday, December 2, 2011 | |
7:30 AM | Registration, Breakfast, and Poster Viewing |
Session I: The Science of Acute Stroke Intervention | |
Session Chairs: Gregory J. del Zoppo, MD, University of Washington and Wolf-Dieter Heiss, MD, Max-Planck Institute, Cologne | |
8:30 AM | Introduction Chair / Co-chair |
8:40 AM | Population Risk Changes: Forecasts and Speculation About the Future of Stroke |
9:00 AM | Pathophysiologically Targeted Therapy of Acute Stroke: Brain And Beyond |
9:20 AM | The Penumbra: How Does Tissue Injury Evolve? |
9:40 AM | How Early Tissue Injury and Intervention Promote Tissue Recovery |
10:00 AM | Coffee Break and Poster Viewing |
10:30 AM | Panel Discussion Session I — all session speakers |
Data Blitz Session — Hot Topic/Updates | |
11:00 AM | Current Treatment of Basilar Occlusion |
| Basilar Artery Occlusion: Time for a Randomised Trial? |
| Third International Stroke Trial of Intravenous Thrombolysis With iv rtPA in Acute Ischaemic Stroke: Baseline Characteristics of the 3035 Patients Randomised |
12:00 PM | Networking Lunch and Poster Viewing |
Lunchtime Workshop: How to Make Acute Intervention More Widely Available | |
1:00 PM | Improving Public Education and Reaction to Stroke Symptoms |
1:15 PM | How to Organize Pre-Hospital Services to Save Time |
1:30 PM | How to Organize the ER to Save Time |
1:45 PM | Panel Discussion |
Session II: Clinical Management of Medical Issues in the Acute Setting | |
Session Chairs: Etsuro Mori, MD, PhD, Tohoku University and Geoffrey A. Donnan, MD, FRACP FRCP, Florey Neuroscience Institutes | |
2:00 PM | Introduction Chair / Co-Chair: Optimization of Patient Selection — Clinical Ramifications |
2:10 PM | Optimization of Patient Selection — Acute Image Acquisition and Relation to Pathophysiology |
2:30 PM | Hyperglycemia and Ischemic Stroke: The SHINE Trial |
2:50 PM | Tissue Injury and Cerebral Blood Flow — the Case for Neuroprotection |
3:10 PM | Combined Intravenous — Intra-Arterial Treatment Approaches: IMS3 |
3:30 PM | Enhancing the Use of Thrombolysis |
3:50 PM | Treatment of Acute Ischemic Stroke: Systemic or Local? |
4:20 PM | Coffee Break and Poster Viewing |
4:50 PM | Panel Discussion Session II — all session speakers |
5:20 PM | Keynote Address 2 |
6:10 PM | Day 2 Concludes |
Day 3: Saturday, December 3, 2011 | |
7:30 AM | Registration, Breakfast, and Poster Viewing |
Session III: Evolution of Tissue Injury | |
Session Chairs: Markku Kaste, MD, PhD, Helsinki University and Werner Hacke, MD, PhD, University of Heidelberg | |
8:30 AM | Introduction Chair / Co-chair |
8:40 AM | Unexpected Roles of Glia in Acute Ischemic Injury |
9:00 AM | Does Inhibiting SURI Complement rtPA in Cerebral Ischemia? |
9:20 AM | Safety and Efficacy of 0.6mg/kg rt-PA — Optimum rt-PA Dose Revisited |
9:40 AM | Ancillary Approaches to Plasminogen Activators |
10:00 AM | Selection of Treatment Responders: Only for the Late Time Window? |
10:20 AM | Coffee Break and Poster Viewing |
10:50 AM | Panel Discussion Session III — all session speakers |
11:20 AM | Keynote Address 3 |
12:10 PM | Networking Lunch and Poster Viewing |
12:50 PM | Poster Session |
Data Blitz Session — Hot Topics/Updates | |
1:50 PM | Aspects on Pretreatment Diffusion Weighted Imaging for Intravenous rt-PA Therapy: Samurai rt-PA Registry |
| Impact of Collateral Perfusion Augmentation in Select Groups of Acute Ischemic Stroke Patients |
| Endovascular Therapy in Young Acute Ischemic Stroke Patients and The Role of Intra-Arterial Vasodilators in the Process of Recanalization |
Session IV: Conditions of Agent Delivery and Its Optimization | |
Session Chairs: John Marler, MD, Rockville, MD, and Thomas G. Brott, MD, The Mayo Clinic | |
2:50 PM | Introduction Chair / Co-Chair: Summary of Clinical Trial Outcomes (What Haven't we Learned?) |
3:00 PM | Rationale For The Timing Of Treatment |
3:20 PM | Intersection of Pre- and In-hospital Care of Stroke |
3:40 PM | Intracranial Arterial Topography and Fragility as Barriers to Endovascular Intervention |
4:00 PM | Paths Forward: When Old Data is Not Enough |
4:20 PM | Panel Discussion Session IV — all session speakers |
4:50 PM | Closing Remarks |
5:15 PM | Conference Concludes |
Keynote Speakers
Gregory J. del Zoppo, MD
University of Washington
Philip B. Gorelick, MD, MPH
University of Illinios at Chicago
Antoine M. Hakim, MD, PhD
University of Ottawa
Speakers
Mark J. Alberts, MD
Northwestern University Feinberg School of Medicine
Andrei V. Alexandrov, MD
University of Alabama at Birmingham
William G. Barsan, MD
University of Michigan Hospital
Joseph P. Broderick, MD
University of Cincinnati
Thomas G. Brott, MD
The Mayo Clinic
Alastair Buchan, MD
University of Oxford, Oxford
Andrew Demchuk, MD
University of Calgary
Ulrich Dirnagl, MD
Center for Stroke Research, Berlin
Geoffrey A. Donnan, MD, FRACP, FRCP
Florey Neuroscience Institutes
James C. Grotta, MD
University of Texas Medical School at Houston
Werner Hacke, MD, PhD
University of Heidelberg
Wolf-Dieter Heiss, MD
Max-Planck Institute for Neurological Research
George Howard, PhD
University of Alabama School of Public Health
Edward C. Jauch, MD, MS, FAHA, FACEP
Medical University of South Carolina
Karen C. Johnston, MD
University of Virginia
Markku Kaste, MD, PhD
Helsinki University Central Hospital
David S. Liebeskind, MD
University of California at Los Angeles
Eng H. Lo, PhD
Massachusetts General Hospital
John R. Marler, MD
Rockville, MD
Etsuro Mori, MD, PhD
Tohoku University Graduate School of Medicine
Maiken Nedergaard, MD, DMSc
University of Rochester Medical School
J. Marc Simard, MD, PhD
University of Maryland School of Medicine
Rüdiger von Kummer, MD, PhD
Technische Universität Dresden
Sponsors
For sponsorship opportunities, please contact Marta Murcia at mmurcia@nyas.org or 212.298.8641.
Bronze Sponsors
Otsuka Pharmaceutical Co., Ltd
Academy Friends
Bristol-Myers Squibb Research and Development
Grant Support
This meeting is part of our Translational Medicine Initiative, sponsored by the Josiah Macy Jr. Foundation and The Mushett Family Foundation.
This project has been supported by Grant Number R13NS077679 from the National Institute Of Neurological Disorders And Stroke (NINDS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Neurological Disorders And Stroke or the National Institutes of Health.
Supported by an educational grant from Talecris Biotherapeutics, Center for Science and Education.
Promotional Partners
American Academy of Cardiovascular Perfusion
Association of Vascular and interventional Radiographers
American Heart Association / American Stroke Association
Cardiovascular and Interventional Radiological Society of Europe
European Atherosclerosis Society
European Federation of Neurological Societies
Journal of Clinical Investigation
Thursday, December 1
Satellite Workshop
Multimodal Neuroimaging: Ultrasound and Catheter Angiography
Andrei V. Alexandrov, MD, Comprehensive Stroke Center, University of Alabama Hospital, Birmingham
Systemic administration of tissue plasminogen activator (tPA) remains the fastest way to initiate treatment for acute ischemic stroke. Since tPA works by induction of partial recanalization of large thrombi, early augmentation of fibrinolysis to improve recanalization is desirable. This augmentation is feasible and can be safely achieved at bedside with 2 MHz pulsed wave Doppler. Transcranial ultrasound delivery in an operator-independent and dose-controlled manner has been successfully tested in healthy volunteers and tPA treated patients (Barlinn K, et al. ISC 2011, Barretto A, et al. ISC 2012).
Catheter angiography and intra-arterial (IA) reperfusion procedures are in continuing development. Compared to IA, iv tPA has lower revascularization rates, yet patients treated with systemic thrombolysis achieve favorable functional outcomes likely due to earlier treatment initiation. Currently, no evidence exists that primary intra-arterial (IA) revascularization could be any better than systemic tPA within the 3 hour time window. Ongoing IMS-3 trial will answer the question whether bridging iv-tPA-IA protocol is any better than systemic tPA alone. Newest technologies like stenting or stentrievers (SARIS, SWIFT trials) offer faster recanalization, and thus have a potential to decrease onset-to-treatment time. In turn, fast endovascular procedures may provide an alternative to systemic tPA, and they should be compared in a randomized trial of a device vs standard of care.
Advanced Multimodal CT/MRI Approaches to Hyperacute Stroke Diagnosis, Treatment and Monitoring
David S. Liebeskind, MD, University of California at Los Angeles
Conference
Keynote Address 1: Acute Treatment of Stroke in Ten Years — How it Will Be Different
Antoine M. Hakim, MD, PhD, University of Ottawa
In 2008, an audit in the United Kingdom estimated that 15% of all stroke patients may be eligible to receive rt-PA but only 1% received it. In the best organized jurisdictions currently, approximately 15% of patients arriving to the Emergency Room within 2.5 hours of stroke onset receive rt-PA when the theoretical maximum may be closer to 50%. The factors contributing to these gaps will be discussed based on the results of the 2011 Audit conducted by the Canadian Stroke Network. Additional means to increase the rate of thrombolysis may include: extending the therapeutic time window, combining thrombolysis with neuroprotection, but the most immediate approach is likely maximizing patient access to the drug through the widespread use of Telestroke. These and other measures, and their likelihood in the next 10 years, will be reviewed.
Travel & Lodging
Our Location
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600
Hotels Near 7 World Trade Center
Recommended partner hotel
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133
The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.
Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.
Other nearby hotels
212.693.2001 | |
212.385.4900 | |
212.269.6400 | |
212.742.0003 | |
212.232.7700 | |
212.747.1500 | |
212.344.0800 |
Special Needs and Additional Information
For any additional information and for special needs, including child/family care resources available to conference attendees, please e-mail dvollmer@nyas.org or call Deanna Vollmer at 212.298.8611.